Abstract
Regulation (EC) 1394/2007 of the European Parliament and the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 allowed the use of non - authorized advanced therapy medicinal products under the certain circumstances. This socalled hospital exemption rule needs to be applied in the each Member State of the European Union individually and for this purpose Member States should provide national procedures and control measures. The aim of this article is to clear up the criteria for hospital exemption listed in Regulation (EC) 1394/2007 and to contrast the difference in implementing hospital exemption rule into national legal regimes on examples of the United Kingdom, Lithuania and Poland.
Keywords: Advanced therapy medicinal product, hospital exemption, regulation.
Current Stem Cell Research & Therapy
Title:Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Volume: 12 Issue: 1
Author(s): Tatjana Ivaskiene, Mykolas Mauricas and Justinas Ivaska
Affiliation:
Keywords: Advanced therapy medicinal product, hospital exemption, regulation.
Abstract: Regulation (EC) 1394/2007 of the European Parliament and the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 allowed the use of non - authorized advanced therapy medicinal products under the certain circumstances. This socalled hospital exemption rule needs to be applied in the each Member State of the European Union individually and for this purpose Member States should provide national procedures and control measures. The aim of this article is to clear up the criteria for hospital exemption listed in Regulation (EC) 1394/2007 and to contrast the difference in implementing hospital exemption rule into national legal regimes on examples of the United Kingdom, Lithuania and Poland.
Export Options
About this article
Cite this article as:
Ivaskiene Tatjana, Mauricas Mykolas and Ivaska Justinas, Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States, Current Stem Cell Research & Therapy 2017; 12 (1) . https://dx.doi.org/10.2174/1574888X11666160714114854
DOI https://dx.doi.org/10.2174/1574888X11666160714114854 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews Current Understanding of the Interplay Between Catechol-OMethyltransferase Genetic Variants, Sleep, Brain Development and Cognitive Performance in Schizophrenia
CNS & Neurological Disorders - Drug Targets Mechanistic Considerations on the Development of Lung Edema: Vascular, Perivascular and Molecular Aspects from Early Stage to Tissue and Vascular Remodeling Stage
Current Respiratory Medicine Reviews Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis
Current Neurovascular Research A Review: Hair Health, Concerns of Shampoo Ingredients and Scalp Nourishing Treatments
Current Pharmaceutical Biotechnology Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science Anionic Linear Globular Dendrimer-G2-Ciprofloxacin Nano-Conjugate: Novel Agent against Wilson Disease Cell Model
Letters in Drug Design & Discovery Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Novel Penetrating Cations for Targeting Mitochondria
Current Pharmaceutical Design Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
Current Chemical Biology Recent Advances in Synthetic Chemistry of Diabetic Research
Mini-Reviews in Medicinal Chemistry Commentary 1 (Research Highlights: Parkinson’s Disease and α-Synuclein: Passing it on)
CNS & Neurological Disorders - Drug Targets